File(s) not publicly available
Global strategy for the diagnosis and management of asthma in children 5 years and younger
Version 2 2024-06-13, 15:21Version 2 2024-06-13, 15:21
Version 1 2022-03-29, 15:55Version 1 2022-03-29, 15:55
journal contribution
posted on 2011-01-01, 00:00 authored by S E Pedersen, S S Hurd, R F Lemanske, A Becker, H J Zar, Peter Sly, M Soto-Quiroz, G Wong, E D BatemanAsthma is the most common chronic disease of childhood and the leading cause of childhood morbidity from chronic disease as measured by school absences, emergency department visits, and hospitalions1. During the past two decades, many scientific advances have improved our understanding of asthma and our ability to manage and control it effectively. However, in children 5 years and younger, the clinical symptoms of asthma are variable and non-specific. Furthermore, neither airflow limitation nor airway inflammation, the main pathologic hallmarks of the condition, can be assessed routinely in this age group. For this reason, to aid in the diagnosis of asthma in young children, a symptoms-only descriptive approach that includes the definition of various wheezing phenotypes has been recommended2. In 1993, the Global Initiative for Asthma (GINA) was implemented to develop a network of individuals, organizations, and public health officials to disseminate information about the care of patients with asthma while at the same time assuring a mechanism to incorporate the results of scientific investigations into asthma care. Since then, GINA has developed and regularly revised a Global Strategy for Asthma Management and Prevention. Publications based on the Global Strategy for Asthma Management and Prevention have been translated into many different languages to promote international collaboration and dissemination of information. In this report, Global Strategy for Asthma Management and Prevention in Children 5 Years and Younger, an effort has been made to present the special challenges that must be taken into account in managing asthma in children during the first 5 years of life, including difficulties with diagnosis, the efficacy and safety of drugs and drug delivery systems, and the lack of data on new therapies. Approaches to these issues will vary among populations in the world based on socioeconomic conditions, genetic diversity, cultural beliefs, and differences in healthcare access and delivery. Patients in this age group are often managed by pediatricians and general practitioners routinely faced with a wide variety of issues related to childhood diseases. Copyright © 2010 Wiley-Liss, Inc.
History
Journal
Pediatric PulmonologyVolume
46Issue
1Pagination
1 - 17Publisher DOI
ISSN
8755-6863eISSN
1099-0496Usage metrics
Categories
No categories selectedKeywords
Science & TechnologyLife Sciences & BiomedicinePediatricsRespiratory Systemasthmaguidelineshumanchildrenchronic diseaseRANDOMIZED CONTROLLED-TRIALINHALED FLUTICASONE PROPIONATEBUDESONIDE INHALATION SUSPENSIONLEUKOTRIENE RECEPTOR ANTAGONISTMETERED-DOSE INHALERHIGH-RISK CHILDRENPRESCHOOL-CHILDRENCHILDHOOD ASTHMAPERSISTENT ASTHMALUNG-FUNCTIONGlobal Initiative for Asthma
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC